>General Information
>Accreditation - CME
>Hotel Information

Officially Endorsed by:

UCSD Sulpizio Cardiovascular Center

American College of Cardiology

Arizona Chapter
California Chapter
Hawaii Chapter
Oregon Chapter
Washington Chapter

The 9th Annual
International Hawaii Symposium on
Diagnostic and Therapeutic Modalities in Heart Failure
A Comprehensive and Practical Review of Advances in
Heart Failure and Biomarkers

December 5-7, 2019

Waikoloa Beach Marriott
Island of Hawaii

Required CME Surveys will be available online once the conference begins. Your registration email address is needed in order for you to login and complete the surveys. Upon completion you will receive your CME Certificate online. Surveys must be completed by December 30, 2019.



This Live activity, 9th Annual International Hawaii Symposium on Diagnostic and Therapeutic Modalities in Heart Failure, with a beginning date of December 5, 2019 is currently being reviewed for up to 15.0 Prescribed credit(s) by an accrediting organization. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AMA: AAFP Prescribed credit is accepted by the American Medical Association as equivalent to AMA PRA Category 1 Credit™ toward the AMA Physician's Recognition Award.

AANPCP: The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts AAFP Prescribed credit.

ANCC: According to the ANCC, the continuing education hours approved by the AAFP meet the ANCC-accredited CNE criteria.

AAPA: The American Academy of Physician Assistants accepts AAFP Prescribed credit for AAPA Category 1 CME credit.

The 9th Annual International Hawaii Symposium on Diagnostic and Therapeutic Modalities in Heart Failure will be held from December 5 - 7, 2019 at the delightful Waikoloa Beach Marriott on the beautiful Island of Hawaii. This year we have put together a program that is designed to provide in-depth coverage of the important advances that have taken place in heart failure over the past year as well as provide an overview of the most effective therapeutic strategies for prevention and treatment. Topics that will be covered through a series of lectures, panel discussions and case presentations include:

     • Benefits of SGLT2 inhibitors in preventing CV events
     • The role of PCSK9 inhibitors
     • Practical approaches for managing hypertension
     • Clinical assessment of HF and use of biomarkers
     • Evaluation and treatment of sleep apnea
     • Incorporating sacubitril/valsartan and ivabradine into clinical practice
     • Recognizing and treating pulmonary arterial hypertension
     • Treating HFpEF
     • Managing hyperkalemia in heart failure
     • NOAC’s for treating CV disease
     • Role of palliative care and hospice
     • Percutaneous approaches for treating vascular and valvular disease
     • Left atrial closure devices
     • Managing drug-drug interactions and drug side effects
     • Use of ICDs and CRT
     • Wearable cardioverter defibrillator
     • Remote monitoring of pulmonary artery pressures as a means of improving
       outcomes in heart failure patients
     • Use of percutaneous and durable mechanical circulatory support
     • Diagnosing and treating amyloid heart disease
     • Efficacy of direct thrombin inhibitors in reducing CV events through
        vascular protection

At the end of the meeting the participant will be better able to:

  1. Implement effective therapy for treating heart failure patients with pharmacologic agents and devices
  2. Recognize the role of new FDA approved heart failure drugs
  3. Describe new anticoagulants to treat atrial fibrillation and other cardiovascular diseases
  4. Define patients who are candidates for the use of left atrial appendage closure devices
  5. Determine how remote monitoring devices and biomarkers help in patient management
  6. Evaluate and manage patients with pulmonary arterial hypertension
  7. Define indications for percutaneous mitral repair and aortic valve replacement
  8. Identify patients who are candidates for ICDs and CRT
  9. Describe the value of a wearable cardioverter defibrillator
  10. Explore the role of biomarkers and how they are most effectively used to manage HF
  11. Identify and treat sleep apnea
  12. Describe new agents to treat hypercholesterolemia and diabetes
  13. Recognize the effects of SGLT2 inhibitors in reducing CV events
  14. Identify effective therapies for treating hyperkalemia
  15. Define the role of mechanical circulatory support devices in improving outcomes in acute and end-stage heart failure
  16. Describe the roles of palliative care and hospice in managing HF patients
  17. Identify and treat cardiac amyloidosis
  18. Define the concept of vascular protection with thrombin inhibitors
  19. Recognize the role of vasodilator therapy with hydralazine-nitrates in heart failure patients

Nearly 6 million Americans (2% of the U.S.) are living with heart failure. An estimated 670,000 new cases of heart failure (HF) are diagnosed each year and this condition is a major cause of morbidity and mortality (80% of men and 70% of women less than 65 years of age who have HF will die within 8 years) and is the number one cause of hospitalizations of the elderly in the U.S. HF is common, but unrecognized and often misdiagnosed. Recent data have shown that drugs and devices that have proven beneficial and are recommended in recent practice guidelines, (HFSA 2010 update of practice guidelines Lindelfield J et al J Cardiac Failure 2010;16: 475) are underutilized (Fonarow GC et al. Circulation 2010;122:585).

Recent information also suggests a significant individual variability in conformity to quality-of-care indicators and clinical outcome of patients with HF and a substantial gap in overall performance. In addition, according to a study analyzing the quality of health care in the U.S. on average, patients with heart failure received the recommended quality of care only 64% of the time (heart failure performance measurement set by the ACC/AHA 2010). Using data from the IMPROVE-HF registry it was found that only 7% of HF patients received all therapies for which they were potentially eligible and use of guideline recommended therapy by practices varied widely (Fonarow GC et al Circ Heart Failure 2008;1:98).

The importance of correcting deficiencies in knowledge and practice is evidenced from the results of recent studies demonstrating that increased use of evidence based, life sustaining therapies and performance measures have a significant impact on the outcome of patients with HF (OPTIMIZE- HF, JAMA 2007; 297: 61).

This Symposium is designed to bring the latest developments in the field of HF and biomarkers. Participants will increase their expertise and innovation in treating cardiovascular disease by attending this symposium which will highlight new advances to optimize patient care.
v The symposium is endorsed by the UC San Diego Sulpizio Cardiovascular Center, and the California, Arizona and Hawaii Chapters of the American College of Cardiology.

The target audience for this activity includes Cardiologists, Internists, Primary Care Physicians, Nurses, PharmDs and Allied Health Care Professionals.